BioAge Labs Statistics
Total Valuation
BioAge Labs has a market cap or net worth of $285.99 million. The enterprise value is -$29.33 million.
Important Dates
The next estimated earnings date is Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioAge Labs has 35.85 million shares outstanding. The number of shares has increased by 1,552.56% in one year.
| Current Share Class | 35.85M |
| Shares Outstanding | 35.85M |
| Shares Change (YoY) | +1,552.56% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 3.64% |
| Owned by Institutions (%) | 46.27% |
| Float | 24.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 55.28 |
| Forward PS | 51.01 |
| PB Ratio | 0.93 |
| P/TBV Ratio | 0.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.21, with a Debt / Equity ratio of 0.03.
| Current Ratio | 13.21 |
| Quick Ratio | 13.09 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -78.53 |
Financial Efficiency
Return on equity (ROE) is -35.88% and return on invested capital (ROIC) is -24.77%.
| Return on Equity (ROE) | -35.88% |
| Return on Assets (ROA) | -23.46% |
| Return on Invested Capital (ROIC) | -24.77% |
| Return on Capital Employed (ROCE) | -30.51% |
| Revenue Per Employee | $60,359 |
| Profits Per Employee | -$1.23M |
| Employee Count | 64 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.21% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -68.21% |
| 50-Day Moving Average | 5.41 |
| 200-Day Moving Average | 4.59 |
| Relative Strength Index (RSI) | 70.94 |
| Average Volume (20 Days) | 606,291 |
Short Selling Information
The latest short interest is 692,983, so 1.93% of the outstanding shares have been sold short.
| Short Interest | 692,983 |
| Short Previous Month | 2.49M |
| Short % of Shares Out | 1.93% |
| Short % of Float | 2.85% |
| Short Ratio (days to cover) | 3.40 |
Income Statement
In the last 12 months, BioAge Labs had revenue of $3.86 million and -$79.03 million in losses. Loss per share was -$2.84.
| Revenue | 3.86M |
| Gross Profit | -7.30M |
| Operating Income | -91.33M |
| Pretax Income | -79.03M |
| Net Income | -79.03M |
| EBITDA | -91.15M |
| EBIT | -91.33M |
| Loss Per Share | -$2.84 |
Full Income StatementBalance Sheet
The company has $297.30 million in cash and $8.75 million in debt, giving a net cash position of $304.66 million or $8.50 per share.
| Cash & Cash Equivalents | 297.30M |
| Total Debt | 8.75M |
| Net Cash | 304.66M |
| Net Cash Per Share | $8.50 |
| Equity (Book Value) | 294.78M |
| Book Value Per Share | 8.22 |
| Working Capital | 278.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$57.40 million and capital expenditures -$916,000, giving a free cash flow of -$58.32 million.
| Operating Cash Flow | -57.40M |
| Capital Expenditures | -916,000 |
| Free Cash Flow | -58.32M |
| FCF Per Share | -$1.63 |
Full Cash Flow StatementMargins
| Gross Margin | -188.92% |
| Operating Margin | -2,364.20% |
| Pretax Margin | -2,045.74% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioAge Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,552.56% |
| Shareholder Yield | -1,552.56% |
| Earnings Yield | -28.70% |
| FCF Yield | -21.18% |
Analyst Forecast
The average price target for BioAge Labs is $9.00, which is 12.82% higher than the current price. The consensus rating is "Hold".
| Price Target | $9.00 |
| Price Target Difference | 12.82% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioAge Labs has an Altman Z-Score of 5.88 and a Piotroski F-Score of 2.
| Altman Z-Score | 5.88 |
| Piotroski F-Score | 2 |
